文献速递泌尿生殖与妇科肿瘤放疗

宫颈癌近距离放疗前肿瘤最大宽度的TRUS与MR前瞻性观察者内/间评估

Prospective intra/inter-observer evaluation of pre-brachytherapy cervical cancer tumor width measured in TRUS and MR imaging.
PubMed 文献 · Radiat Oncol · 2019-10-04

结果显示TRUS与MR在FIGO I/II期肿瘤中评估等效,在更晚期肿瘤中TRUS稍逊但仍与金标准成像保持良好一致性。

要点

  • TRUS与MR测量宫颈癌近距离放疗前肿瘤最大宽度的平均差异小,观察者内和观察者间一致性均较高。
  • FIGO I/II期肿瘤中TRUS的观察者间ICC与MR相当,提示TRUS可等效替代MR评估肿瘤宽度。
  • 更晚期肿瘤中TRUS观察者间ICC低于MR但仍可接受,MR仍为金标准。

核心结论

  • TRUS在评估宫颈癌FIGO I/II期近距离放疗前肿瘤最大宽度方面与MR等效。
  • 在更晚期阶段TRUS似乎稍逊于MR,但仍与金标准成像保持良好一致性。

研究设计与样本

  • 首次近距离放疗植入前无施源器状态下行MR和TRUS扫描,由三名检查者独立盲法分析,结合临床信息测量肿瘤最大宽度。
  • 采用组内相关系数(ICC)、Passing-Bablok回归和Bland-Altman图评估观察者内和观察者间测量一致性。

主要发现

  • MR与TRUS测量的肿瘤宽度平均差异分别为1.3±3.2 mm(p<0.001)、1.1±4.6 mm(p=0.01)和0.7±3 mm(p=0.01)。
  • 三名观察者测量误差小于3 mm的比例分别为79%、82%和80%。
  • 观察者内ICC分别为0.96(95%CI 0.94-0.97)、0.93(95%CI 0.9-0.95)和0.96(95%CI 0.95-0.98)。
  • HRCTVMR宽度的观察者间ICC为0.92(95%CI 0.89-0.94),FIGO分期之间无差异;HRCTVTRUS的观察者间ICC为0.86(95%CI 0.81-0.9)。
  • FIGO I和II期肿瘤中HRCTVTRUS的ICC值与相应HRCTVMR的ICC值相当;更大肿瘤中HRCTVTRUS观察者间ICC低于相应HRCTVMR但仍可接受。

临床怎么用

  • 在宫颈癌FIGO I/II期患者中,可考虑使用TRUS替代MR评估近距离放疗前肿瘤最大宽度。
  • 更晚期肿瘤中TRUS一致性稍低,解读结果时需结合MR金标准。

局限性

  • 原文未明确报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ultrasound (US) imaging has been proved as an excellent diagnostic tool in gynecology and, due to its wide availability and limited cost, is under intense investigation as base for dose adaptation in cervical cancer brachytherapy. Purpose of this work is to test inter/intra-observer uncertainties between magnetic resonance (MR) and trans-rectal ultrasound (TRUS) imaging in defining maximum tumor width before first brachytherapy (BT) application in a prospective cohort of cervical cancer patients undergoing image-guided adaptive brachytherapy (IGABT). METHODS: One hundred ten consecutive cervical cancer patients treated between 2013 and 2016 were included. Before the first BT implant patients underwent MR and TRUS scan with no applicator in place. Images were independently analyzed by three examiners, blinded to the other's results. With clinical information at hand, maximum tumor width was measured on preBT TRUS and MR. Quantitative agreement analysis was undertaken. Intra-class correlation coefficient (ICC), Passing-Bablok and Bland Altman plots were used to evaluate the intra/inter-observers measurement agreement. RESULTS: Average difference between tumor width measured on MR (HRCTVMR) and TRUS (HRCTVTRUS) was 1.3 ± 3.2 mm (p < 0.001); 1.1 ± 4.6 mm (p = 0.01) and 0.7 ± 3 mm (p = 0.01). The error was less than 3 mm in 79, 82 and 80% of the measurements for the three observers, respectively. Intra-observer ICC was 0.96 (CI95% 0.94-0.97), 0.93 (CI95% 0.9-0.95) and 0.96 (CI95% 0.95-0.98) respectively. Inter-observer ICC for HRCTVMR width measures was 0.92 (CI95% 0.89-0.94) with no difference among FIGO stages. Inter-observer ICC for HRCTVTRUS was 0.86 (CI95% 0.81-0.9). For FIGO stage I and II tumors, ICC HRCTVTRUS values were comparable to respective HRCTVMR ICC values. For larger tumors HRCTVTRUS inter-observer ICC values were lower than respective HRCTVMR although remaining acceptable. CONCLUSIONS: Our results suggest that TRUS is equivalent to MR in assessing preBT tumor maximum width in cervical cancer FIGO stage I/II. In more advanced stages TRUS seems to be slightly inferior to MR although maintaining a good agreement to gold standard imaging.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Federico M, Hernandez-Socorro CR, Ribeiro I, et al. Prospective intra/inter-observer evaluation of pre-brachytherapy cervical cancer tumor width measured in TRUS and MR imaging. Radiat Oncol. 2019. PMID: 31585543. doi:10.1186/s13014-019-1352-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。